Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 2
1996 1
1997 1
2001 1
2003 2
2004 1
2005 1
2006 6
2009 4
2010 2
2011 2
2012 2
2013 3
2014 2
2015 5
2016 4
2017 3
2018 4
2020 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Byrd JC, et al. Among authors: sukbuntherng j. N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19. N Engl J Med. 2013. PMID: 23782158 Free PMC article. Clinical Trial.
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Okhuysen PC, Ramesh MS, Louie T, Kiknadze N, Torre-Cisneros J, de Oliveira CM, Van Steenkiste C, Stychneuskaya A, Garey KW, Garcia-Diaz J, Li J, Duperchy E, Chang BY, Sukbuntherng J, Montoya JG, Styles L, Clow F, James D, Dubberke ER, Wilcox M. Okhuysen PC, et al. Among authors: sukbuntherng j. Clin Infect Dis. 2024 Feb 2:ciad792. doi: 10.1093/cid/ciad792. Online ahead of print. Clin Infect Dis. 2024. PMID: 38305378
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
de Jong J, Hellemans P, De Wilde S, Patricia D, Masterson T, Manikhas G, Myasnikov A, Osmanov D, Córdoba R, Panizo C, de Zwart L, Snoeys J, Chauhan V, Jiao J, Sukbuntherng J, Ouellet D. de Jong J, et al. Among authors: sukbuntherng j. Leuk Lymphoma. 2018 Dec;59(12):2888-2895. doi: 10.1080/10428194.2018.1460474. Epub 2018 May 30. Leuk Lymphoma. 2018. PMID: 29846137 Clinical Trial.
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.
de Jong J, Skee D, Murphy J, Sukbuntherng J, Hellemans P, Smit J, de Vries R, Jiao JJ, Snoeys J, Mannaert E. de Jong J, et al. Among authors: sukbuntherng j. Pharmacol Res Perspect. 2015 Aug;3(4):e00156. doi: 10.1002/prp2.156. Epub 2015 Jun 24. Pharmacol Res Perspect. 2015. PMID: 26171235 Free PMC article.
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC. Barr PM, et al. Among authors: sukbuntherng j. Blood. 2017 May 11;129(19):2612-2615. doi: 10.1182/blood-2016-12-737346. Epub 2017 Apr 3. Blood. 2017. PMID: 28373262 Free PMC article. Clinical Trial.
45 results